CEO and co-founder
Joe Driscoll is an entrepreneur and manager who specializes in helping small companies grow. Joe has worked as a manager and a consultant to managers and boards of growth companies and turnarounds, providing strategy and business planning. Joe served as executive vice president of an investment advisor company, responsible for product sales through a partnership with a global investment management firm, and responsible for new product development. Prior to this, Joe served as a private equity manager responsible for the acquisition, managerial oversight, and growth of an industrial manufacturing business doubling revenues and tripling net income, before selling the company to a larger competitor. Joe has served as a CFO for a private diversified holding company, with its primary portfolio focus in real estate redevelopment. Joe began his career as an options trader and member of the New York Mercantile Exchange.
Joe serves as the CEO of Evol Science which he co-founded and built with scientists out of Fox Chase Cancer Center. At Evol our AI-driven Systems Biology Platform identifies and targets cancer cell drug resistance, acquired and intrinsic, accelerating and de-risking drug development and clinical translation. We generate a novel pipeline for our BioPharma partners and license out our IP. Our first biological discovery in the MAPK pathway has yielded multiple novel drug combinations, causing synthetic lethality, by exploiting cross-signaling and off-target effects in RAS mutated cancers. We expect to have our first combination in proof-of-principle clinical trials in the first half of 2019.
Joe received his B.A. from Harvard College, and his M.B.A. from Harvard Business School.